



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 6 May 2019 (#14)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- [New FAQs](#) for NIH-MRC U.S.-South Africa Collaborative Research
- **The multiple PI approach for new investigators.** If you are a new investigator and want to submit a multiple PI grant application, consider the benefits versus the potential downsides. For example, if a new investigator has an established investigator as the second PI, the application **is not eligible for the special new investigator payline**. For more information, visit NIAID's [Multiple Principal Investigators](#) page.
- Notice of Intent to Publish a Funding Opportunity Announcement for **Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research (R21 Clinical Trial Not Allowed)** ([NOT-OD-19-100](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for **Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)** ([NOT-OD-19-104](#))

1. HIV/AIDS Clinical Trials Units (UM1 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-AI-19-045](#))

Type: UM1

Application Due Date: November 18, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for Clinical Trials Units (CTUs) to provide scientific and administrative expertise as well as the infrastructure to conduct clinical studies developed by NIH HIV/AIDS Clinical Trials Networks. Clinical Trials Units will participate in the development of trials and provide clinical sites, local laboratory capacity, and pharmacy support for two or more HIV/AIDS Clinical Trials Networks. NIAID is soliciting applications for FY21 award consideration for the following HIV/AIDS Clinical Trials Networks:

- [RFA AI-19-003](#): HIV/AIDS Adult Therapeutics Clinical Trials Network
- [RFA AI-19-004](#): HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network
- [RFA AI-19-005](#): HIV Prevention Clinical Trials Network
- [RFA AI-19-006](#): HIV Vaccines Clinical Trials Network

Research Priority Areas for each of the HIV/AIDS Clinical Trials Networks can be found on the NIAID website [here](#).

The CTU provides the scientific and administrative expertise as well as the infrastructure to participate in **two or more NIH HIV/AIDS Clinical Trials Networks**. Each CTU must demonstrate sufficient breadth and depth of scientific expertise to contribute to the ongoing refinement of the clinical trials network(s) agenda (i.e., the research priority areas of the network(s) as described in the companion FOAs), participate in an array of clinical studies, demonstrate a productive partnership with the community(ies) in which they propose to conduct research, promote efficient utilization of resources and infrastructure, and include continuous performance evaluation and interventions to drive compliance.

Budget: NIAID intends to commit an estimated total of up to \$62.0M for Core funds in FY21 for 30-35 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project based on the size/scope of the CTU. For example, a CTU participating in 2-3 NIH HIV/AIDS Clinical Trials Networks and comprising 3-4 CRSs may expect core funding within the range of \$1.0M-\$2.0M total direct cost. The scope of the proposed project should determine the project period. The maximum period is 7 years.

2. Biological Testing Facility Access For Contraceptive Development (X01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-263\)](#)

Type: X01

Application Due Date: July 1, 2019, December 16, 2019, May 1, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NICHD has a state-of-the art Biological Testing Facility for advancing male and/or female non-hormonal contraception development with the capabilities and capacity for preclinical and Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., fertility studies, pharmacology, toxicology, reproductive tract histopathology, sperm morphology). The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program.

Budget: Not Applicable. There is no budget associated with X01 Resource Access Awards. The scope of the proposed project should determine the project period. The maximum project period is one year.

3. Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-264\)](#)

Type: R01

Application Due Date: July 10, 2019; December 10, 2019; July 10, 2020; December 10, 2020; July 9, 2021; December 10, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. The scope of the proposed project should determine the project period

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105